Paysign, Inc. (PAYS) Earnings Call Transcript & Summary
August 5, 2026
Earnings Call Speaker Segments
Mark Newcomer
executiveKevin, thank you — and hello everyone, good afternoon. We're glad you could join us as Paysign discusses how we performed in the second quarter of 2026. I'm Mark Newcomer, and I hold the titles of President and Chief Executive Officer. Joining me is Jeff Baker, who serves as our Chief Financial Officer. Also here are Matt Turner, who leads Patient Affordability as President, and Matt Lanford, our Chief Payments Officer; once our prepared comments wrap up, both of them will be available during Q&A. We put out our second quarter numbers earlier today, and those results established fresh highs across revenue, net income, and adjusted EBITDA. In fact, this is now the second consecutive quarter in which we exceeded the guidance we had given for the period. Given that performance, we are raising our outlook for the entire year as of today. The momentum on display reflects a strategic choice made a few years back to put money into patient affordability as a business capable of complementing plasma and boosting our overall growth trajectory. This quarter serves as a solid illustration of that effort continuing to deliver returns. To frame the quarter, revenue climbed 48% year-over-year, reaching $28.3 million. Net income was $6.8 million, or $0.11 per fully diluted share, which is a near 5-fold increase year-over-year. Gross margin widened 170 basis points to 63.3%. Jeff will take you through all the quarter's financial results, but these figures plainly show the progress underway in the business. Patient affordability turned in another outstanding quarter and remains the company's principal growth engine. We saw revenue climb 89% compared with the same period a year earlier, reaching $14.6 million, while claim volume came in about 54% higher than it did in last year's second quarter. Those figures show how new program wins are stacking up, how much more our current clients are using, and how our biggest pharma partnerships keep growing. We're growing the company in a disciplined way, and when you put strong growth together with margin expansion and a positive contribution margin, it's clear this approach is delivering. Another encouraging sign is that plasma is now part of that same success. Margin widened in both of our business lines this quarter: patient affordability keeps compounding as it matures, and plasma has moved beyond the challenges that held it back for most of the past 1.5 years. That's the equilibrium we've been aiming for — a dependable core that throws off cash, underwriting a platform that expands more quickly and earns higher margins. During the opening six months of 2026, over $900 million in financial assistance has moved through that platform to patients. To put that in perspective, across all of 2025 we delivered just about $1 billion, and in only half a year we've already gotten close to matching that twelve-month total. This speed mirrors two things: a broader set of programs and heavier usage among programs that have been running for at least a year. It also demonstrates just how essential Paysign has become when it comes to preserving access for patients to therapies that carry a high cost. A key reason pharma companies keep moving more of their operations to us is our Dynamic Business Rules technology. During the first six months of the year, it protected customers from over $300 million in expenses that would have been shifted elsewhere by co-pay maximizers and accumulator programs. For comparison, the figure for all of 2025 was roughly $325 million — so in just half a year, we've nearly matched an entire year's worth of savings. That shows both the scale of the platform and how much better our detection logic continues to become. In Q2, we rolled out 13 new programs. We closed the quarter with 148 active programs, versus 97 at the same point last year. That matches our expectations and reflects steady, rapid expansion. As the year progresses, launch activity typically accelerates, and Q2 was a clear step up from the insurance plan year transitions and resets that make Q1 our busiest stretch. The pipeline remains strong throughout the remainder of 2026 and well into 2027, and we expect to match or beat the 55 net additions we recorded in 2025. When you put it all together — a larger program count, higher utilization, and the assistance dollars we put to work — the message is consistent. Our platform is expanding without friction, and interest from the market in the solutions we offer for patient affordability continues to grow. Turning now to the business of compensating plasma donors. Revenue from plasma during the quarter reached $13 million, which represents a 21.4% increase compared with $10.7 million during the same period last year. A more telling figure was the monthly revenue generated per center, which came to $7,699 — the strongest number recorded since the third quarter of 2024. That statistic reinforces our confidence that the center closures we recently undertook were strategic in nature, as donors shifted to other centers nearby within the same network rather than leaving the system altogether; at the close of the quarter, we were operating 561 centers, a figure that accounts for the 19 closures we mentioned during last quarter's call, partially offset by 7 newly added locations. What we're seeing gives us growing conviction that the challenges we ran into are mostly in the rearview now. On top of that, plasma remains a dependable engine of cash, and it gives us a ready way in to expand how widely our donor management and engagement software gets adopted across the collectors we work with. Our life sciences technology lineup, sold under the Apherion name, continues to work its way through the regulatory review for our Blood Establishment Computer Software, or BECS, donor management system. We're eager to report more milestones as that effort progresses. The Apherion platform continues to draw strong interest domestically and overseas. To support that international demand, we set up Apherion Technologies Limited, a wholly owned subsidiary domiciled in Ireland, which will serve as our European hub anchoring sales development and client support. Since roughly 1/3 of sourced plasma is collected outside of the United States, much of it by companies that also run U.S. operations, we see substantial international runway for this business, and this step puts us in position to pursue it. In summary, the second quarter confirmed the strategy we have spent the past several years building toward. Patient affordability is scaling, plasma is steady and cash generative, and our life science technology efforts are opening another meaningful avenue for growth. As we head into the second half of the year, our business is picking up speed, our margins are getting wider, and we have a pipeline extending all the way into 2027. This isn't just about beating some number — it's about an operation that's truly scaling. In our view, Paysign is well positioned to continue delivering durable growth and long-term value for shareholders, for the clients who trust us, and for the patients who ultimately benefit from what we build. With that, I'll turn it over to Jeff, who can go into more detail about our second-quarter results.
Jeff Baker
executiveThanks, Mark, and good afternoon to all of you. We turned in yet another robust quarter. The performance of our plasma segment as well as our patient affordability offerings demonstrates the momentum that has continued to build. Beyond that, we achieved margin gains compared with the prior year throughout the whole income statement, and that holds true even after setting aside a onetime, noncash gain of $990,000 tied to the carrying value of the earn-out liability from the Gamma acquisition. Looking at our first 2 quarters of 2026, 2 things stand out. Pharmaceutical companies are clearly responding well to our patient affordability solutions; and our plasma business has bounced back from the elevated inventory positions that dragged down results all through 2025. Turning to the second quarter, total revenues climbed 48.1% versus the same period last year, reaching $28.3 million. Pharma revenue paced the growth, rising 88.9% year-over-year to $14.6 million. That expansion came from ongoing program growth, which included 51 net pharma patient affordability programs introduced during the trailing 12 months. We finished the quarter with 148 active programs, while processed claims rose roughly 54% against the second quarter of 2025. Higher monthly management fees, set-up fees, claim processing fees, customer service contact center support and other billable services like Dynamic Business Rules all contributed to the revenue gain. Once again this year, pharma revenue exceeded plasma revenue, even given the usual seasonal trend where claims start to fall off and plasma donations typically rise as the year progresses. Plasma revenue grew 21.4% year-over-year to $13 million. Average monthly revenue per center rose by more than 5% to $7,699, compared with $7,098 in the second quarter of 2025. Additionally, the average number of loads per center climbed again versus a year ago. This gain came mainly from better utilization at centers we already operate rather than from adding locations, which is an encouraging sign regarding underlying donor activity. As Mark mentioned, we closed the quarter with 561 centers, matching the expectations we shared during our first quarter earnings call. These patterns reinforce our belief that the inventory surplus from 2025 has mostly worked its way through the system. Gross profit margin widened to 63.3% from 61.6% during the same period last year, driven by a larger share of pharma revenue, which generates higher gross margins than our plasma segment. Call center support, implementation, processing and commission costs combined rose far less than our 48.1% revenue growth, and that is what drove the margin improvement while showcasing the operating leverage built into our model. Total operating expenses came in at $10.9 million, up 5.5% from $10.3 million in the second quarter of 2025. In the quarter, we booked a nonrecurring, noncash gain of $990,000 tied to the carrying value of the earn-out liability from the Gamma acquisition. If you set that gain aside, total operating expenses would have totaled $11.9 million, a 15.1% rise over the prior year and far under our 48.1% revenue growth. Selling, general and administrative expenses rose 4.3% to $8.5 million, which includes stock-based compensation of $1.3 million. Without the onetime gain, selling, general and administrative expenses would have grown 16.3% to $9.5 million. Operating leverage stood out as one of the quarter's key achievements. If we leave out the one-time Gamma earn-out benefit, adjusted operating margin — which we figure by taking adjusted operating income and dividing it by revenue — grew to 21.3%, up from 7.5% in the second quarter of 2025, which works out to a gain of over 1,300 basis points. To frame it differently, about half of the extra revenue we brought in was turned into adjusted operating income, which shows how scalable the platform is as pharma mix rises and plasma returns to normal. Depreciation and amortization came in $200,000 higher, mostly because of amortization tied to intangible assets from the Gamma acquisition along with capitalized costs for new software development. A handful of other notable items from the second quarter: income before taxes rose to $7.9 million, compared with $2 million in the second quarter of 2025. The company recorded an income tax provision of $1.1 million, which produced an effective tax rate of 14.5%, versus 32.1% in the second quarter of 2025. That lower rate comes from discrete item adjustments, mainly tied to our stock price being higher at June 30, 2026 than in the same period a year earlier, which boosted the tax benefit from stock-based compensation relative to the prior year period. GAAP net income for the quarter was $6.8 million, or $0.11 per fully diluted share, up from $1.4 million, or $0.02 per fully diluted share, in the second quarter of 2025. Adjusted EBITDA rose 113% to $9.6 million, or $0.16 per fully diluted share, versus $4.5 million, or $0.08 per fully diluted share, in the second quarter of 2025. Adjusted EBITDA margin grew to 34% from 23.7% a year ago. We rely on adjusted EBITDA, which strips out stock-based compensation and one-time noncash adjustments, to assess core operating performance. The fully diluted share count applied when calculating per share amounts was 62 million shares, against 57.9 million shares in the prior year period. We closed the quarter with $27.4 million in unrestricted cash and 0 bank debt. Restricted cash rose $5.2 million from year-end December 31, 2025, reaching $149 million. That increase came mainly from customer program deposits for plasma and pharma programs, plus higher funds on card, meaning balances loaded onto cards that cardholders haven't spent yet. Before I move to our outlook, I'd like to point out that our second quarter results beat guidance on every line of the income statement once again, largely on the strength of our patient affordability business. Revenue of $28.3 million came in above the high end of our $26.2 million to $26.7 million guidance range. Gross margin of 63.3% landed above our guided range of 60% to 62%. Adjusted EBITDA of $9.6 million topped the high end of our $7.7 million to $8.5 million range. And adjusted net margin of 20.4% came in above the top of our 13.4% to 15% range. The outperformance in the first 2 quarters of the year, together with the visibility we have on program launches and seasonal trends, backs our raised full year outlook. Looking ahead to the whole of 2026, our projection now calls for total revenue between $114 million and $117 million, which works out to 39% to 43% growth versus the prior year. That's roughly a $7 million bump at the midpoint relative to what we told you before, and the main reasons are a patient affordability business performing better than we anticipated plus a rebound in plasma. Because higher patient affordability revenue keeps pushing margin expansion and operating leverage forward, we're looking for gross profit margins of 62% to 63%, up from the 60% to 62% we previously guided. On a GAAP basis, net income should land somewhere between $21.5 million and $23 million, equal to $0.35 to $0.37 per diluted share. Adjusted EBITDA, meanwhile, should come in at $35 million to $38 million, or $0.57 to $0.61 per diluted share. Those full year net income figures incorporate the nonrecurring, noncash Gamma earn-out benefit that was recorded in the second quarter. In line with how we present adjusted results, that benefit is left out of adjusted EBITDA. Turning to the third quarter, we're anticipating revenue of $28.5 million to $30 million, up 32% to 38.9% from the same period a year ago, with roughly $300,000 of that from other revenue and the rest divided between patient affordability and plasma. Gross margins should fall in the 61% to 63% range, which mirrors a heavier plasma revenue mix. For the quarter, our tax rate should be 17%, while GAAP net income should reach $5.7 million to $6.0 million, or $0.09 to $0.10 per fully diluted share. Adjusted EBITDA should total $9.5 million to $10 million, or $0.15 to $0.16 per fully diluted share. Based on what we're announcing today, 157 active patient affordability programs are in place, and we anticipate finishing the third quarter with 165 to 170 of them active. We also look for our count of active plasma centers to edge up a bit from the second quarter. Keep in mind that pharma revenue tends to peak during the first half, since claims are highest when annual insurance deductibles reset, then it settles down over the remainder of the year. Plasma revenue behaves differently — it's usually weakest in the first quarter and then climbs as donor activity gets back to normal once tax refund season passes. Our full year guidance already accounts for both of these patterns. Bottom line, we're heading into the back half of 2026 with better program momentum, improved plasma utilization, fatter margins and a clean balance sheet; all of that underpins our updated guidance and our belief in the platform's long-term earnings power. That wraps up what I had prepared; at this point, I'll hand the call back to the operator so we can move into the question-and-answer session.
Gary Prestopino
analystMark, at this stage, have you thought about — or actually gone and quantified — what the revenue growth per program looks like on a same-store basis, for the programs you've been running for roughly 12 months?
Matt Turner
executiveYeah. Sorry — Matt here. Could you say that again? Do you mean plasma, or do you mean patient affordability?
Gary Prestopino
analystOn the topic of what patients can afford, if you could.
Matt Turner
executiveSo what you're getting at is, on a month-over-month basis, how does that appear — what does it look like once things settle into a normal pattern?
Gary Prestopino
analystNo. I just want to get a sense of—for the programs you've had in hand for 12 months, how does that look on something like a same-store basis? Within a program, or across your programs, what has the organic growth been, for want of a better term?
Jeff Baker
executiveYes, so Gary, generally speaking, holding everything constant year over year, once a program reaches maturity, you'd anticipate revenue growth that's fairly flat. That said, we've been layering additional feature functionality into a program, and a program might receive extra education. A number of factors come into play. I mean, there are certain programs where we're activating other services that we now charge for. So it's somewhat difficult to give you a precise answer. Had we done nothing, had we done absolutely nothing, you'd expect that if there were x number of claims 1 year, the same number of claims would occur next year; but in fact we're seeing growth across some of our existing programs, since we're introducing more products and services for those programs; we have a couple of brands that are receiving more indications, which means there are other uses for the drug, and that widens their opportunity. So that's what we're seeing right now.
Gary Prestopino
analystAll right, so essentially the majority of that expansion will keep coming from bringing on additional programs. That's the point I was attempting to make.
Jeff Baker
executiveWithout a doubt.
Gary Prestopino
analystAt some point, Jeff, I believe you and I spoke, and you mentioned that potential pharmaceutical programs number somewhere from 850 to 900. Does that figure still hold up?
Matt Turner
executiveYeah, this is Matt. It's significantly larger than that. What I'd say is roughly 850 drugs right now carry something like maximizer and accumulator impact; however, when you count all the drugs on the market that have a co-pay program, you're talking tens of thousands, essentially every branded product plus most biosimilars; beyond that, you move into certain medical devices too, and you move into products that physicians administer or infuse, so a tremendous TAM remains for us to capture. To return to an analogy from 2 quarters back, we're still sitting in the first inning here.
Gary Prestopino
analystAll right. That sounds excellent; and finally, I recall you said a bit about the Apherion program requiring approval, so might you elaborate on that a little further, regarding what you're awaiting here prior to being able to bring it to market?
Mark Newcomer
executiveYeah. What I'd say is the regulatory path is genuinely something we are currently working through. There isn't — since I lack a crystal ball, whenever you find yourself in that fresh process, it pretty much is what it is and you simply go along with it. Giving a specific date isn't really possible for me right now. Still, you should assume we're going to keep at it — we're receiving a great deal of interest from abroad and here at home, and my expectation is that will carry on. As things move forward and milestones on that get reached, we will certainly provide you with further updates.
Gary Prestopino
analystSo the regulatory approval you're waiting on comes from the FDA, is that right?
Mark Newcomer
executiveThat's right.
Gary Prestopino
analystAlright, and then one final thing — that TAM is quite large, likely more than $1 billion on a global basis, right?
Jeff Baker
executiveThe TAM just for software, specifically for blood and plasma software, worldwide right now, comes to $3.5 billion. And according to estimates from a third-party resource that we reference, that figure will reach $7 billion across the coming 10 years.
Jacob Stephan
analystCongratulations on a truly solid quarter. Now, regarding the Q3 program guide — Q3 suggests about 20 additions during that period. Seasonally, that's quite robust, especially since Q3 tends to be a softer quarter. But if you consider that Q4 is generally stronger and connect that to your guidance of more than 55, what do you think is different about Q3 that produces such a strong sequential figure for additions?
Matt Turner
executiveLet me challenge one assumption there. For us, Q3 isn't usually a sluggish quarter. Our weakest period for new program launches tends to be Q1, because of insurance resets. So looking at this quarter — in this year's first quarter, we launched only a couple of programs, and that matches what we anticipate. By late Q1 and heading into Q2, there's the Asembia conference we mention annually, and that begins to lay the groundwork for this year's second half and next year's first half. So what's arriving in Q3 now reflects sales efforts that started back in Q1 during that launch slowdown, plus some items that emerged and that we essentially finalized at Asembia and managed to push through. Now, on the nonportfolio accounts — set aside the massive, top 10 pharmas for a moment. With the smaller pharmas, our sales cycle remains at roughly 90 days. So when we were arranging these things in Q2, clearly — you apply that 90-day window and it begins pointing toward Q3. And as Jeff mentioned, here we are on August 5 and we've already completed numerous launches over the past 30 days. So yes, I don't believe there's any particular factor at play; it's simply the usual timing we anticipate for these kinds of deals to materialize. And Q4 consistently tends to match Q3, since we've got — many folks will hurry to get programs up and running before Q1, when insurance deductibles and all of that reset, and we enter what we refer to as the blizzard, where every patient is calling about everything, every pharmacy is calling about everything, because they're handling insurance deductibles resetting and all the rest. So that's really what drives Q3 and Q4 — getting everything finished ahead of Q1, because no one wants to transition a program during Q1. And generally, what you'll observe in terms of launches in Q1, and occasionally as much as Q2, are new programs that are — this is a new-to-market drug, rather than seeing us transition very many programs in January or February, simply because of resource constraints throughout the wider industry.
Jeff Baker
executiveAs I mentioned, Jacob, where we stand right now is that July closed with 157 programs, meaning 9 more have been brought on since the quarter ended. You know, during Q4 of last year, 28 programs were brought in. Our pipeline looks incredibly robust; we're optimistic about the direction we're going and the count of programs, with 13 added. Q2 was quite strong too. Yet when you look at the guidance we've provided, well, the pipeline remains robust, implementations continue to arrive, and nothing is slowing down.
Jacob Stephan
analystUnderstood. Thanks for walking through all of that. Perhaps one final thing, sort of piggybacking on what the previous analyst asked; how does the opening 12 months of revenue for a given program stack up against your more established base? And do you usually lead with DBR? Or does that tend to be something added on and sold later?
Matt Turner
executiveOur standard approach is to try and roll out with DBR. That said, this applies to specialty products affected by maximizers; that doesn't mean every single product we handle faces maximizer impact. So you get somewhat of a blend. As for your second question about what a program actually looks like, I believe that's quite hard to answer. Let me just — I brought up a few quick figures on a program we moved over in July of '24. Comparing January of '25 with January of '26, claims rose by roughly 15%; none of that relates to Paysign. It stems from that drug getting a pediatric indication during Q4 of '25; as a result, entering Q1 of '26, its claim volume is naturally elevated. On the flip side, I have a different drug running maybe 7% lower in that program compared with the prior year, yet I won't notice it, since I actually hold the drug that's taking business away from that product. Frequently, when a pharma company has a drug beginning to hit its loss of exclusivity window, they'll bring out a different drug, sometimes; similar indications, comparable treatment profile, adverse events and pharmacovigilance, efficacy. Everything along those lines is quite alike, except it's a fresh molecule. And they'll introduce that product in a manner meant to pull business away from the one that's — that's going off exclusivity. So there's — you simply can't make a blanket statement that this is how programs operate. It's comparable to asking, "Hey, what does a drug cost?" when you'd have to factor in aspirin alongside gene therapy. Gene therapy runs $30 million, aspirin costs less than pennies per pill; so once we're inside our programs, that degree of disparity exists. I've got — we have programs that may generate a couple of claims each month. I've got programs that may generate 30,000 claims each month. There's simply no way to hand you an average and claim this is what to expect from a program, and this is how they appear year over year. You truly need to be tuned in to the drug's efficacy, the pipeline, the manufacturer, all of it. And regrettably, given our contracts, we simply cannot reveal our book of business.
Peter Heckmann
analystIt's nice to see these solid results. Turning back to pharma, maybe you could explain how procurement actually happens for the manufacturers, or for the intermediaries who deal with them? Is it usually done through a request for proposal, or does it tend to happen more on a one-off basis? That said, when you look at it, is there some way to assess your win rates — Paysign clearly has strong momentum in this business, but it makes me curious whether your win rates have actually climbed fairly significantly. And then, regarding seasonality of wins, looking at just the past 2 years, there doesn't appear to be any genuine consistent pattern, but I suppose, broadly speaking, would you anticipate winning comparatively more new programs during the first half or the second half?
Matt Turner
executiveOn win ratios — let me start with the sales cycle, since that was your initial question. We see a fairly healthy blend of RFPs/RFIs as opposed to direct award. I'd estimate that at present, roughly 75% of the wins we get originate from RFPs/RFIs. The other 25% comes via word-of-mouth, essentially direct awards. When it comes to RFPs, our win rate is quite strong. I don't have precise figures with me right now; I'd need to go back and pull that out. But we don't — I'd say our RFI/RFP win rate exceeds 80%. If you — okay. That covered the first question. Now I've forgotten your second one, since I didn't jot it down. My apologies — what was that next one?
Peter Heckmann
analystI'm curious whether there's any seasonality when it comes to these wins. Looking back, I'm just attempting to — I believe the fourth quarter last time around was an excellent quarter for net wins. Yet during that same year, the opening quarter was also quite robust. So I'm just wondering, are there particular conferences or specific launch timings such that, generally speaking, we'd anticipate you bringing on more net new in the first half compared with the second half, or does it simply vary by year?
Matt Turner
executiveYeah. I'd say transition wins do carry some seasonality, though I don't believe that's really tied to selling. It has more to do with figuring out what timing makes sense for actually moving the program over. There are some — actually a fair number of programs that we might already know we've secured and have been holding onto for 4, 5 months since the launch date falls mid-year, because that's what suited the manufacturer. I sort of compare it to constructing a house up in Alaska. Nobody builds during winter. So we don't move programs over in the middle of a blizzard. That essentially eliminates this entire 3 or 4-month stretch of the year where you simply won't witness many transitions. However, if you examine our business wins this year, it's roughly 50 to 50 between transition programs and new to market, which explains why some of these programs are launching during the first quarter and the second quarter. They're brand-new to market drugs. We've secured those products via RFP or via word of mouth. And we — those arrive gradually across the year, and that depends on the PDUFA dates they got from the FDA along with their internal launch readiness for those products. So selling definitely has a seasonal pattern; we bring up Asembia frequently. That conference matters enormously to us annually, and we devote substantial time, energy and resources toward it. We regard it as our biggest single marketing event focused on patient affordability across the entire year. We also show up at 5 to 7 additional conferences at differing levels, where we might send 1 or 2 people, or for certain ones we have 10 or 12 folks attend. It truly hinges on the conference and who we believe will be present that's on our target list. Asembia falls in the April/May window, and then we reach the October/November window with a couple of other conferences located in the — usually in like the Philadelphia area or New Jersey area each year. So those are — I'd say that's where the seasonality in our sales comes from. Regarding win rates, here's something I want to bring up since it just crossed my mind. Take last year and every new program that launched — some share of those we simply had no shot at winning, correct? Maybe they're locked into exclusivity deals with the vendor they already use, or it's a small drug heading to a manufacturer that's already exclusive with another company. But we went back and examined that last year. Of all the new drugs reaching the market, we captured more than 80% of the RFIs/RFPs that were issued. So our win rate and conversion rate are extremely strong across the board. And when you stack us against everyone else in the market, I doubt you'll find another player launching 50 to 60 programs annually. Before I joined here, I worked at a different service provider, and I can tell you we definitely weren't averaging more than 1 program per month. So I'd say our growth is clearly pacing the industry.
Peter Heckmann
analystThat's excellent. Really useful detail. Then, Jeff, there's something I wanted to ask you specifically. My apologies if it already came up — it's earnings season, and there's a lot happening. Over the past 3 years, the gap between your EBITDA in Q3 and in Q4 was generally fairly consistent; but this year, as I work through your third quarter and full year guidance, it looks like Q3 will be extremely strong on margin, while Q4 won't be as strong, and in absolute dollar terms there's a fairly large step-down in Q4. So forgive me if this was covered, but could you explain what's driving that? It seems like more than just the usual revenue mix shifting back toward plasma.
Jeff Baker
executiveNo, fair question. If you go back to last year, we launched so many patient affordability programs during the fourth quarter. It was honestly like drinking from a firehose. This year, hopefully, we're seeing somewhat more in Q2 and more in Q3, some in Q4. So it's spread a bit more evenly across the remainder of the year. That's one piece of it. Another thing you'll notice in Q4, and something I've been through, is that it's the holiday season. Like anyone else, we've got employees who take time off; that affects some of the capitalization rates on the software development side. So I expect it to come in lower. My tax rate — which I realize has no effect on adjusted EBITDA — is simply higher in Q4 than in Q3, because we have all of the — a lot of the vestings, the RSUs coming through. We run more campaigns in Q3 than in Q4, so my deductions decline. So at present, looking at Q4, I'd anticipate my income tax rate there to be nearer to 27% against the guidance of 17% for Q3. So it's a combination of factors. Also, this year, as I mentioned, our pipeline is strong, and we plan to bring on more account managers to support the patient affordability business, add more claims people, and so on. We need to be ready in Q1 when the floodgates open. So you're seeing some of that too. I could be wrong, but as things stand, that's what I expect.
Jon Hickman
analystHere's a modeling-type question for you folks. Looking ahead, would 15% year-over-year be a solid rate of growth when it comes to your OpEx?
Jeff Baker
executiveJon, to be honest, that isn't something I actually watch. My approach is a bottoms-up build. No guidance has been provided by me for the coming year, though my expectation would be that the bulk of our expansion — from a hiring standpoint — is driven by patient affordability, and that will keep going as more programs get added. So it's — 15% doesn't strike me as unreasonable. Perhaps slightly on the low side. But 15% to 20%-ish probably isn't crazy. I'd go back and say, okay, during the prior year, 51 programs were added by us. In the current year, we're on track to add 55 to 60 programs. You can see how the OpEx is building, strip out stock comp along with some of the D&A, should you want to examine just SG&A on its own, and my sense is you could likely draw some solid inferences from those figures.
Jon Hickman
analystAll right. And after that, maybe you could discuss whether you'll be present at any events or similar things over the next few months, from an Investor Relations standpoint?
Jeff Baker
executiveSure. We have a few non-deal road shows underway, plus a number of conferences. Among the conferences we'll be at is one in New York during September — mid-September — that's the Lake Street Conference, and we're also attending an Oppenheimer Conference. There's a non-deal road show heading to Boston. In August, we're attending the IDEAS Conference in Chicago. So over the coming couple of months, we'll be traveling quite a lot.
Operator
operatorThank you. That brings our Q&A portion to a close. And folks, with that, we're wrapping up today's teleconference and webcast. At this point you're welcome to disconnect your lines, and we hope the rest of your day is wonderful; thanks so much for joining us today.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Paysign, Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Paysign, Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Paysign, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.